Cartalax Molecular Structure & Chemical Properties

Cartalax represents a unique class of bioregulatory peptides with over three decades of preclinical research focused on cellular aging and connective tissue function. Developed by Professor Vladimir Khavinson in the 1990s, this synthetic tripeptide mimics a sequence found in type XI collagen and was isolated from kidney tissue extracts. Unlike traditional receptor-targeting peptides, Cartalax operates through direct DNA binding to modulate gene expression at the transcriptional level. Its small molecular size (333 Da) enables cellular and nuclear penetration, while two acidic amino acid residues provide DNA-binding properties through minor groove interactions.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide’s sequence corresponds to a motif found in type XI collagen, a structural protein critical for cartilage organization and extracellular matrix integrity. This structural similarity is hypothesized to contribute to Cartalax’s tissue-specific effects on connective tissues.

Cartalax Mechanism of Action

Cartalax operates through a fundamentally different mechanism than traditional receptor-based peptides, functioning primarily as a gene expression modulator through direct DNA interactions. Research suggests that Cartalax binds to specific DNA sequences in the minor groove, particularly targeting promoter regions of genes involved in cellular aging, proliferation, and tissue maintenance. This epigenetic approach allows the peptide to influence multiple downstream pathways simultaneously, creating coordinated effects across various cellular processes.

Primary Cellular Pathways

DNA-Binding and Gene Expression Modulation

Research has demonstrated that Cartalax forms energetically favorable complexes with specific DNA motifs, particularly the sequence d(ATATATATAT)2 within the DNA minor groove[1]. This direct binding mechanism enables:

• Transcriptional regulation of genes involved in cellular senescence and aging
• Modulation of chromatin structure affecting gene accessibility
• Coordinated changes in expression of multiple related genes
• Tissue-specific effects based on promoter availability

Studies using molecular modeling revealed that Cartalax’s small size and charged amino acids facilitate nuclear entry and DNA recognition without requiring receptor-mediated transport[2].

Cellular Senescence Marker Regulation

Investigations in aging cell cultures have shown that Cartalax significantly affects key senescence-associated proteins[3]. Major findings include:

• Decreased p53 expression by up to 25% in aging fibroblasts and kidney cells
• Reduced p16 and p21 levels, both cyclin-dependent kinase inhibitors limiting cell cycle progression
• Increased SIRT-6 expression, a sirtuin linked to genomic stability and longevity
• Upregulation of proliferation markers including Ki-67 by 20-30% in various cell types

These coordinated changes suggest Cartalax shifts cells from a senescent state toward a more youthful expression pattern.

Proliferation and Anti-Apoptotic Signaling

Research in fibroblast cultures demonstrates that Cartalax enhances cellular proliferation while reducing programmed cell death[4]. Key mechanisms include:

• Enhanced Ki-67 expression indicating active cell division
• Upregulation of CD98hc (SLC3A2), a marker associated with cellular regeneration
• Reduced caspase-3 activity, the primary executioner enzyme in apoptosis pathways
• Decreased caspase-dependent apoptosis in both young and aged cell cultures

These effects appear mediated through altered gene expression rather than direct enzyme inhibition.

Extracellular Matrix Homeostasis

Studies reveal that Cartalax influences extracellular matrix maintenance through multiple pathways[5]:

• Inhibition of MMP-9 synthesis, a metalloproteinase that increases during aging and degrades matrix components
• Enhanced production of collagen and proteoglycans in cartilage models
• Improved structural integrity of connective tissues
• Reduced excessive matrix breakdown in aging cells

Nuclear Factor-Kappa B (NF-kB) Modulation

Research indicates Cartalax may upregulate NF-kB transcript levels, though consequences remain incompletely understood[6]. Potential implications include:

• Modulation of inflammatory response pathways
• Coordination of stress response mechanisms
• Possible immunomodulatory effects
• Balancing of pro-inflammatory and anti-inflammatory signals

Cartalax Research Applications & Key Findings

Cellular Aging and Senescence Research

Fibroblast Aging and Skin Cell Studies

Extensive investigations in aging fibroblast cultures have examined Cartalax’s effects on cellular senescence markers[7]. Key findings include:

• Enhanced proliferation measured by Ki-67 expression increases of 20-30% in aging cell cultures
• Reduced expression of aging markers p53, p16, and p21 across multiple passage levels
• Increased CD98hc expression associated with cellular regeneration capacity
• Improved microcirculation and functional activity in skin fibroblast studies

Studies using immunofluorescent confocal microscopy revealed that Cartalax effects were consistent across different passage numbers, suggesting applicability to both young and aged cells[8].

Kidney Cell Renewal Research

Research in renal epithelial cell cultures has demonstrated Cartalax’s potential effects on kidney aging[9]. Major observations include:

• Increased cell proliferation in kidney tissue cultures from both young and old animals
• Decreased expression of senescence markers p53, p16, and p21 in aging kidney cells
• Upregulation of SIRT-6 linked to DNA repair and cellular longevity
• Potential for supporting kidney cell renewal mechanisms during aging

Comparative studies showed that while Cartalax demonstrated activity, it was less potent than complex polypeptide extracts, suggesting synergistic effects may occur with longer peptide sequences[10].

Mesenchymal Stem Cell Research

Bone Marrow Stem Cell Aging Studies

Investigations in bone marrow mesenchymal stem cells revealed Cartalax’s influence on stem cell aging processes[11]. Research findings include:

• Modulation of gene expression patterns associated with stem cell senescence
• Changes in 1.6- to 5.6-fold expression levels for genes including IGF1, FOXO1, TERT, TNKS2, and NF-kB
• Potential for maintaining stem cell regenerative capacity during aging
• Effects on cellular differentiation pathways

Chondrogenic Differentiation Research

Studies examining cartilage-forming stem cells demonstrated Cartalax’s tissue-specific effects[12]:

• Enhanced chondrocyte proliferation in both young and aged rat models
• Increased production of cartilage-specific extracellular matrix components
• Upregulation of type II collagen and proteoglycan synthesis
• Improved cartilage tissue organization and structural integrity

Connective Tissue and Cartilage Research

Cartilage Homeostasis Studies

Research in cartilage models has examined Cartalax’s effects on tissue maintenance and regeneration[13]. Key findings include:

• Stimulation of chondrocyte proliferation measured by PCNA (proliferating cell nuclear antigen) expression
• Balanced regulation promoting matrix synthesis while reducing degradation
• Enhanced resilience and elasticity of cartilage tissue
• Potential applications in osteoarthritis research models

Studies in rabbit models showed that cartilage defects treated with peptide complexes containing Cartalax filled with hyaline-like cartilage rather than inferior fibrocartilage.

Matrix Metalloproteinase Regulation

Investigations across multiple tissue types consistently demonstrated Cartalax’s effects on matrix-degrading enzymes[14]:

• Reduced MMP-9 expression in aging fibroblast and cartilage cultures
• Upregulation of tissue inhibitors of metalloproteinases (TIMPs)
• Shift from catabolic (degrading) to anabolic (building) state in cells
• Anti-fibrotic implications through proper matrix structure maintenance

Cartalax Pharmacokinetics & Metabolism

Absorption & Distribution

Cartalax exhibits unusual pharmacokinetic properties for a peptide, with research demonstrating rapid cellular uptake despite its small size and charged nature[15]. Following administration in rodent studies:

• Rapid cellular penetration achieved within minutes of administration
• Nuclear localization observed, consistent with DNA-binding mechanism
• Distribution to target tissues including skin, kidney, cartilage, and connective tissues
• Small molecular size (333 Da) facilitates cellular entry without requiring specific transport mechanisms

The peptide’s ability to cross cellular and nuclear membranes distinguishes it from larger bioactive peptides that rely on receptor-mediated endocytosis.

Metabolism & Elimination

The metabolic fate of Cartalax remains incompletely characterized, though available preclinical data suggests[16]:

• Rapid cellular uptake in rodent models at doses of 10 micrograms/kg/day
• Effects persisting beyond expected plasma half-life due to gene expression changes
• Likely degradation through standard peptidase pathways
• Minimal accumulation detected in chronic dosing studies (animal models)

A notable characteristic is that biological effects persist for hours to days despite presumed rapid clearance, suggesting the peptide’s primary action occurs at the gene expression level with downstream effects continuing after the peptide itself is metabolized.

Excretion Pathways

Limited pharmacokinetic data indicates[17]:

• Probable renal elimination of peptide and metabolites
• Standard amino acid recycling following peptide degradation
• No evidence of tissue accumulation in available animal studies
• Excretion kinetics require comprehensive investigation

The disconnect between the peptide’s presumed short circulation time and prolonged biological effects highlights the unique nature of its gene expression-modulating mechanism versus traditional receptor-based peptides.

Cartalax Research Protocols & Administration

Dosing in Published Research

Research investigations have employed various Cartalax doses depending on model system and experimental design:

• Rat studies: 10 micrograms/kg body weight is most common in aging research
• Mouse models: Similar dose ranges used in cellular aging studies
• Cell culture: Nanomolar to micromolar concentrations depending on cell type
• Rabbit studies: 10 micrograms/kg in cartilage injury models

Important: These are experimental doses used in animal studies and cannot be extrapolated to other species due to significant differences in metabolism, gene expression patterns, tissue distribution, pharmacokinetics, and peptide degradation rates. Species-specific factors profoundly influence both efficacy and safety profiles.

Administration Routes in Research

Multiple delivery methods have been investigated in preclinical studies:

• Subcutaneous injection – Most common route in animal aging studies; provides systemic delivery
• Intraperitoneal injection – Used in some rodent studies for controlled dosing
• Oral administration – Investigated in Russian clinical practice; bioavailability in capsule form
• Sublingual delivery – Explored for direct absorption through oral mucosa

Common Model Organisms

Cartalax has been studied across multiple experimental systems:

• Rats – Primary animal model for aging studies and tissue regeneration research
• Mice – Used for genetic and aging mechanism studies
• Rabbits – Employed in cartilage injury and repair investigations
• Cell culture systems – Fibroblasts (skin, kidney), chondrocytes, mesenchymal stem cells from various species
• Tissue explants – Kidney tissue cultures, cartilage fragments for mechanistic studies

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite over 30 years of preclinical research, Cartalax faces substantial translational barriers that limit its research utility and prevent clinical application.

Lack of Human Clinical Data

The most significant limitation is the complete absence of published human clinical trials:

• No peer-reviewed human clinical trials exist in international scientific literature
• No Phase I, II, or III studies published in indexed journals
• Human safety profile completely unestablished through rigorous clinical testing
• Optimal human dosing unknown and cannot be reliably extrapolated from animal studies
• Long-term effects in humans unstudied

Some anecdotal reports exist from Russian clinical practice, but these lack the rigor of controlled clinical trials and have not been published in peer-reviewed journals.

Mechanistic Understanding Gaps

Fundamental aspects of Cartalax’s mechanism require clarification:

• Specific DNA sequences targeted by the peptide incompletely characterized
• Complete catalog of affected genes and pathways unknown
• Tissue specificity mechanisms not fully understood
• Whether effects vary by age, sex, or genetic background remains unexplored
• Relationship between DNA binding and downstream cellular effects requires detailed mapping

Long-Term Safety Considerations

Critical safety questions remain unanswered:

• Chronic use effects beyond several weeks unstudied even in animal models
• Potential for unintended gene expression changes unknown
• Effects on cancer risk or tumor growth uninvestigated
• Interaction potential with other peptides or medications uncharacterized
• Reproductive and developmental toxicity inadequately studied

Regulatory & Competitive Sport Status

FDA Position

Cartalax has not received FDA approval for any indication:

• Not approved as a pharmaceutical agent
• Not recognized as GRAS (Generally Recognized as Safe) for food or supplement use
• Not approved for human or veterinary medical applications
• Not legally available for medical compounding in the United States for therapeutic purposes
• Classification as a research chemical only

The FDA has not issued specific guidance on bioregulatory peptides as a class, but individual peptides lacking approval cannot be marketed for human use.

WADA Prohibition

World Anti-Doping Agency status:

• Bioregulatory peptides may fall under prohibited substance categories
• Peptides affecting gene expression could be considered performance-enhancing
• No approved therapeutic use in competitive sports
• Athletes should consult WADA prohibited list for current status

Research Classification: Cartalax is available only for laboratory research use. It is not intended for human consumption, medical use, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

References

1. Khavinson, V.K., Tarnovskaia, S.I., & Lin’kova, N.S. (2014). Tripeptides slow down aging process in renal cell culture. Advances in Gerontology, 27(4), 651-656. PubMed
   
2. Khavinson, V.K., Solovyov, A.Y., & Shataeva, L.K. (2013). Molecular model of short peptide binding to DNA. Bulletin of Experimental Biology and Medicine, 154(6), 808-810. PubMed
   
3. Chalisova, N.I., Lin’kova, N.S., Nichik, T.E., Ryzhak, A.P., Dudkov, A.V., & Ryzhak, G.A. (2015). Peptide regulation of cells renewal processes in kidney tissue cultures from young and old animals. Bulletin of Experimental Biology and Medicine, 159(1), 124-127. PubMed
   
4. Lin’kova, N.S., Drobintseva, A.O., Orlova, O.A., Kuznetsova, E.P., Polyakova, V.O., Kvetnoy, I.M., & Khavinson, V.K. (2016). Peptide regulation of skin fibroblast functions during their aging in vitro. Bulletin of Experimental Biology and Medicine, 161(1), 175-178. PubMed
   
5. Khavinson, V., Linkova, N., Diatlova, A., Gutop, E., & Orlova, O. (2020). Short peptides: regulation of skin function during aging. Advances in Gerontology, 33(1), 46-54. PubMed
   
6. Khavinson, V.K., Lin’kova, N.S., & Tarnovskaya, S.I. (2016). Short peptides regulate gene expression. Bulletin of Experimental Biology and Medicine, 162(2), 288-292. PubMed
   
7. Lin’kova, N.S., Drobintseva, A.O., Orlova, O.A., Kuznetsova, E.P., Polyakova, V.O., Kvetnoy, I.M., & Khavinson, V.K. (2016). Peptide regulation of skin fibroblast functions during their aging in vitro. Bulletin of Experimental Biology and Medicine, 161(1), 175-178. PubMed
   
8. Gutop, E.O., Diatlova, A.S., Linkova, N.S., Orlova, O.A., Trofimova, S.V., & Khavinson, V.K. (2019). Aging of skin fibroblasts: genetic and epigenetic factors. Advances in Gerontology, 32(6), 908-914.
9. Chalisova, N.I., Lin’kova, N.S., Nichik, T.E., Ryzhak, A.P., Dudkov, A.V., & Ryzhak, G.A. (2015). Peptide regulation of cells renewal processes in kidney tissue cultures from young and old animals. Bulletin of Experimental Biology and Medicine, 159(1), 124-127. PubMed
   
10. Khavinson, V.K., Tarnovskaia, S.I., & Lin’kova, N.S. (2014). Tripeptides slow down aging process in renal cell culture. Advances in Gerontology, 27(4), 651-656. PubMed
    
11. Ashapkin, V., Khavinson, V., Shilovsky, G., Linkova, N., & Vanuyshin, B. (2020). Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Molecular Biology Reports, 47(6), 4323-4329. PubMed
    
12. Linkova, N., Khavinson, V., Diatlova, A., Myakisheva, S., & Ryzhak, G. (2023). Peptide regulation of chondrogenic stem cell differentiation. International Journal of Molecular Sciences, 24(9), 8415. PubMed
    
13. Myakisheva, S., Linkova, N., Polyakova, V., & Ryzhak, G. (2023). Peptides of cartilage tissue: regulation of chondrocyte proliferation, geroprotection and prospects for use in osteoarthrosis. Vrach, 34(10), 54-58.
14. Chalisova, N.I., Linkova, N.S., Zhekalov, A.N., Orlova, A.O., Ryzhak, G.A., & Khavinson, V.K. (2014). Short peptides stimulate skin cell regeneration during ageing. Advances in Gerontology, 27(4), 699-703.
15. Khavinson, V.K. (2002). Peptides and ageing. Neuroendocrinology Letters, 23(Suppl 3), 11-144. PubMed
    
16. Khavinson, V.K., & Anisimov, V.N. (2009). Peptide regulation of aging: 35-year research experience. Bulletin of Experimental Biology and Medicine, 148(1), 94-98. PubMed
    
17. Anisimov, V.N., & Khavinson, V.K. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology, 11(2), 139-149. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. Cartalax is intended for laboratory research use only.